Loading clinical trials...
Loading clinical trials...
The purpose of this study is to find out if atovastatin, when taken with a cholinesterase inhibitor, is effective for treating Alzheimer's disease.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
NCT07033494 · Early Alzheimer's Disease
NCT06159673 · Alzheimer's Disease Psychosis
NCT07457138 · Subjective Cognitive Decline (SCD), Functional Cognitive Disorder, and more
NCT07214727 · Alzheimer's Disease
NCT07422857 · Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia
Pfizer Investigational Site
Sun City, Arizona
Pfizer Investigational Site
Fresno, California
Pfizer Investigational Site
Laguna Hills, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions